ACCREDITATION AND CREDIT DESIGNATION
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professions Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
Identify mechanisms and management considerations for acute and delayed toxicities associated with CAR T-cell therapies.
Compare traditional CAR T-cell therapies with emerging alternative effector-cell platforms, including NK-cell and macrophage-based approaches.
Analyze emerging engineering strategies designed to improve the safety, durability, and efficacy of cellular therapies.
Evaluate emerging applications of cellular therapy in autoimmune diseases, hematologic malignancies, and solid tumors.
Assess clinical and toxicity considerations associated with cellular therapies across pediatric, adolescent and young adult, and adult populations.
Appraise the advantages and limitations of allogeneic versus autologous cellular therapy approaches in contemporary practice.
TARGET AUDIENCE
This activity is designed for basic and translational researchers, hematology and medical oncology physicians and fellows, immunologists, and other healthcare professionals interested in tumor immunology and cellular immunotherapy.